natgillin/translations-raw huggingface dataset:
Also contact your doctor immediately: - if your rash worsens, OR - if you develop other symptoms with a rash such as:
Odmah se javite liječniku i u slučaju: - ako Vam se osip pogorša, ILI - ako razvijete osip s drugim popratnim simptomima kao što su:
Replicons with single substitutions at position 155 or 156 and double variants with substitutions at residues 36 and 155 showed cross-resistance to all protease inhibitors tested with a wide range of sensitivities.
Replikoni s jednom supstitucijom na položaju 155 ili 156 i dvostruke varijante sa supstitucijama na reziduama 36 i 155 pokazali su ukriženu rezistenciju na sve inhibitore proteaze ispitane u širokom rasponu osjetljivosti.
It is therefore very important that you read the package leaflets that are provided with these medicines, too.
Stoga je jako važno da pročitate i upute o lijeku priložene uz navedene lijekove.
If co-administered, no dose adjustment is required.
Ako se primjenjuju zajedno, nije potrebna prilagodba doze.
The Marketing Authorisation Holder shall agree to the format and content of the healthcare professional educational pack with the National Competent Authority prior to launch in the Member State.
Nositelj odobrenja usuglasit će se s nacionalnim nadležnim tijelom oko oblika i sadržaja edukacijskog paketa za zdravstvene djelatnike prije stavljanja lijeka u promet u državi članici.
Table 2 provides dosing recommendations as a result of drug interactions with INCIVO.
Tablica 2 donosi preporuke za doziranje kao rezultat interakcija lijekova s INCIVOM.
A dose adjustment of metformin may be necessary.
Može biti potrebno prilagoditi dozu metformina.
Extent and features of Cutaneous Reactions
Opseg i značajke kožnih reakcija
The difference in SVR rates (95% confidence interval) between the T12/PR and Pbo/PR groups was 33 (26, 39).
Razlika u postotku SVR-a (95%-tni interval pouzdanosti) između skupina T12/PR i Pbo/PR iznosila je 33 (26, 39).
rifampicin to treat some infections like tuberculosis (antimycobacterial)
rifampicin za liječenje nekih infekcija poput tuberkuloze (antimikobakterijski lijekovi)
T12/PR All Patients
T12/PR Svi bolesnici
Replicon variants generated from patient-derived sequences showed similar results.
Varijante replikona stvorene iz sekvenca deriviranih iz virusa izoliranih u bolesnika pokazale su slične rezultate.
The rash reported during INCIVO combination treatment was assessed as a typically pruritic, eczematous rash, and involved less than 30% of body surface area.
Osip zabilježen tijekom kombiniranog liječenja INCIVOM bio je procijenjen kao tipično praćen svrbežom i ekcematozan, a zahvaćao je manje od 30% površine tijela.
• Incidence of rash and severe cutaneous reactions
• Incidenciju osipa i teških kožnih reakcija
Patients experiencing mild to moderate rash should be monitored for signs of progression; however, progression was infrequent (less than 10%).
Bolesnike koji razviju blagi do umjereni osip treba pratiti zbog znakova progresije osipa, međutim, progresija osipa nije bila često (manje od 10%).
In clinical trials, the majority of patients were administered antihistamines and topical corticosteroids.
U kliničkim ispitivanjima većini bolesnika primijenili su se antihistaminici i topikalni kortikosteroidi.
The rash may take several weeks to resolve.
Za povlačenje osipa može biti potrebno i nekoliko tjedana.
An effect of telaprevir on UDP-glucuronyltransferases cannot be ruled out and may affect the plasma concentrations of abacavir or zidovudine.
Učinak telaprevira na UDP-glukuroniltransferaze ne može se isključiti i može utjecati na koncentracije abakavira ili zidovudina u plazmi.
The potential clinical significance of these findings is uncertain.
Moguće kliničko značenje ovih nalaza nije poznato.
atazanavir/ritonavir, darunavir/ritonavir, fosamprenavir/ritonavir, lopinavir/ritonavir to treat HIV infections (HIV-protease inhibitors)
atazanavir/ritonavir, darunavir/ritonavir, fosamprenavir/ritonavir, lopinavir/ritonavir za liječenje HIV infekcije (inhibitori HIV-proteaze)
There are no data from the use of INCIVO in pregnant women.
Ne postoje podaci o primjeni INCIVA u trudnica.
Co-administration should be done in a setting which ensures clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation.
Smiju se istodobno primjenjivati u okruženju u kojem je osigurano kliničko praćenje i odgovarajuće medicinsko zbrinjavanje u slučaju respiratorne depresije i/ili produljene sedacije.
Telaprevir is a strong inhibitor of the important drug metabolising enzyme CYP3A4.
Telaprevir je snažni inhibitor važnog metabolizirajućeg enzima CYP3A4.
↑ alfentanil ↑ fentanyl
↑ alfentanil ↑ fentanil
Rat offspring exposed to telaprevir in utero showed normal body weight at birth.
Potomstvo štakora izloženo telapreviru in utero imalo je normalnu tjelesnu težinu pri rođenju.
(7.0-8.9 g/dl or any decrease ≥ 4.5 g/dl)
(7,0-8,9 g/dl ili bilo koje smanjenje ≥ 4,5 g/dl)
Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin, therefore, extreme care must be taken to avoid pregnancy in female patients and
Ribavirin je imao značajne teratogene i/ili embriocidne učinke u svih životinjskih vrsta koje su mu bile izložene, stoga je potreban krajnji oprez kako bi se izbjegla trudnoća u bolesnica i partnerica muških
Dosing of the animals did not result in any exposure-margin when compared to human exposure.
Doziranje u životinja nije rezultiralo drugačijom granicom izloženosti od izloženosti u ljudi.
Drug interactions need to be carefully taken into account, see sections 4.4 and 4.5.
Potrebno je pažljivo uzeti u obzir interakcije lijekova, vidjeti dijelove 4.4 i 4.5.
Multiple metabolites were detected in faeces, plasma, and urine.
Višestruki metaboliti otkriveni su u stolici, plazmi i mokraći.
Other medicinal products associated with severe cutaneous reactions should be used with caution during administration of INCIVO combination treatment to avoid potential confusion as to which medicinal product could be contributing to a severe cutaneous reaction.
Druge lijekove povezane s teškim kožnim reakcijama treba primjenjivati s oprezom tijekom kombiniranog liječenja s INCIVOM kako bi se izbjegla mogućnost zabune pri određivanju koji od lijekova može pridonositi teškoj kožnoj reakciji.
T12/PR All Patients N=540
T12/PR Svi bolesnici N = 540
In vitro studies performed with human Caco-2 cells indicated that telaprevir is a substrate of P-glycoprotein (P-gp).
In vitro ispitivanja provedena na ljudskim stanicama Caco-2 pokazala su da je telaprevir supstrat P-glikoproteina (P-gp).
Rarely patients may have other symptoms with the rash that may be a sign of a severe skin reaction.
Bolesnici rijetko mogu imati osip popraćen drugim simptomima koji mogu biti znak teške kožne reakcije.
On-treatment virologic failure during telaprevir treatment was predominantly associated with higher-level resistant variants, and relapse was predominantly associated with lower-level resistant variants or wild-type virus.
Virološki neuspjeh tijekom liječenja telaprevirom bio je pretežno povezan s rezistentnijim varijantama, a relaps je pretežno bio povezan s manje rezistentnim varijantama ili s divljim tipom virusa.
Moderate rash: Diffuse rash ≤ 50% of body surface area
Umjereni osip: difuzni osip zahvaća ≤ 50% površine tijela
INCIVO in combination with peginterferon and ribavirin is not recommended in patients with platelets < 90,000/mm
INCIVO u kombinaciji s peginterferonom i ribavirinom se ne preporučuje u bolesnika s trombocitima < 90.000/mm
Based on in vitro studies, telaprevir may potentially increase plasma concentrations of medicinal products in which excretion is dependent upon multidrug and toxin extrusion (MATE)-1 and MATE2-K (see table 2).
Na temelju in vitro ispitivanja, telaprevir potencijalno može povisiti koncentracije u plazmi lijekova u kojih je izlučivanje ovisno o ekstruziji transportera više lijekova i toksina (MATE)-1 i MATE2-K (vidjeti tablicu 2).
Table 8 shows SVR rates for patient subgroups.
Tablica 8 pokazuje stope SVR prema podskupinama bolesnika.
The pharmacokinetic properties of telaprevir have been evaluated in healthy adult volunteers and in subjects with chronic HCV infection.
Farmakokinetička svojstva telaprevira bila su procijenjena u zdravih odraslih ispitanika i osoba s kroničnom HCV infekcijom.
The SVR rate for the T8/PR group was 72% (261/364) (P < 0.0001 compared to Pbo/PR48 group).
Stopa SVR u skupini T8/PR bila je 72% (261/364) (P < 0,0001 u usporedbi sa skupinom Pbo/PR48).
Purpose of the medicine alfuzosin to treat symptoms of an enlarged prostate (alpha-1-adrenoreceptor antagonists)
Svrha uzimanja lijeka alfuzosin za liječenje simptoma povećane prostate (antagonisti alfa-1-adrenergičkih receptora)
Severe, potentially life-threatening and fatal skin reactions have been reported with INCIVO combination treatment, including DRESS, SJS, and TEN (see section 4.4).
Teške, potencijalno po život opasne i fatalne kožne reakcije prijavljene su uz kombinirano liječenje s INCIVOM, uključujući DRESS, SJS i TEN (vidjeti dio 4.4).
Telaprevir inhibits organic anion transporter polypeptides (OATPs) OATP1B1 and OATP2B1.
Telaprevir inhibira organske anionske transportne polipeptide (OATP-ove) OATP1B1 i OATP2B1.
In the case of a serious skin reaction, discontinuation of other medicinal products known to be associated with serious skin reactions should be considered.
U slučaju ozbiljne kožne reakcije mora se razmotriti prekid liječenja drugim lijekovima za koje se zna da su povezani s ozbiljnim kožnim
The following laboratory evaluations (complete blood count with white blood cell differential counts, electrolytes, serum creatinine, liver function tests, TSH, uric acid) must be conducted in all patients prior to initiating INCIVO combination treatment.
Sljedeće laboratorijske pretrage (kompletna krvna slika s diferencijalnom krvnom slikom, elektrolitima, serumskim kreatininom, pretragama funkcije jetre, TSH i mokraćnom kiselinom) moraju se provesti u svih bolesnika prije početka kombiniranog liječenja INCIVOM.
P < 0.001, T12/PR compared to Pbo/PR48.
P < 0,001, T12/PR u usporedbi s Pbo/PR48.
HCV/HBV (hepatitis B virus) co-infection There are no data on the use of INCIVO in patients with HCV/HBV co-infection.
Istodobna HCV/HBV (virus hepatitisa B) infekcija Ne postoje podaci o primjeni INCIVA u bolesnika s istodobnom HCV/HBV infekcijom.
If the rash does not improve within 7 days following INCIVO discontinuation, ribavirin should be interrupted.
Ako se osip ne poboljša unutar 7 dana nakon prekida primjene INCIVA, treba prekinuti primjenu ribavirina.
No specific antidote is available for overdose with INCIVO.
Ne postoji specifičan antidot za predoziranje INCIVOM.
Mechanism of action Telaprevir is an inhibitor of the HCV NS3•4A serine protease, which is essential for viral replication.
Mehanizam djelovanja Telaprevir je inhibitor HCV NS3•4A serinske proteaze, koja je neophodna za replikaciju virusa.
For moderate rash that progresses, permanent discontinuation of INCIVO should be considered.
Za umjereni osip koji je progresivan, potrebno je razmotriti trajni prestanak primjene INCIVA.
The mean elimination half-life after single-dose oral administration of telaprevir 750 mg typically ranged from about 4.0 to 4.7 hours.
Prosječno poluvrijeme eliminacije nakon primjene jednokratne peroralne doze telaprevira od 750 mg obično se kretalo u rasponu od približno 4,0 do 4,7 sati.
In both rats and dogs, AST/ALT elevations were observed in most studies, of which the increase in ALT in rats was not normalised after recovery.
U većini ispitivanja bilo je primijećeno povišenje AST/ALT i u štakora i u pasa, s tim da se povišenje ALT u štakora nije normaliziralo nakon oporavka.
In case of overdose you may experience nausea, headache, diarrhoea, decreased appetite, abnormal
U slučaju predoziranja možete osjetiti mučninu, glavobolju, proljev, smanjeni apetit, promijenjen osjet
Studies using recombinant human CYP supersomes showed that telaprevir was a CYP3A4 inhibitor, and a time- and concentration-dependent inhibition of CYP3A4 by telaprevir was observed in human liver microsomes.
Ispitivanja pomoću rekombinantnih ljudskih CYP supersoma pokazala su da je telaprevir inhibitor CYP3A4, a inhibicija CYP3A4 telaprevirom ovisna o vremenu i koncentraciji bila je primijećena u mikrosomima ljudske jetre.
Peginterferon alfa may be continued unless interruption is medically indicated.
Peginterferon alfa može se nastaviti primjenjivati ako ne postoji medicinska indikacija za prekid njegove primjene.
For moderate rash that progresses to severe (≥ 50% body surface area), permanently discontinue INCIVO (see below).
Kod umjerenog osipa koji prelazi u težak (≥ 50% površine tijela), primjenu INCIVA treba trajno prekinuti (vidjeti niže).
Telaprevir is partly metabolised in the liver by CYP3A and is a P-glycoprotein (P-gp) substrate.
Telaprevir se djelomično metabolizira u jetri putem CYP3A i supstrat je P-glikoproteina (P-gp).
Co-administration with inducers may lead to lower exposure of telaprevir with risk of lower efficacy.
Istodobna primjena s induktorima može dovesti do manje izloženosti telapreviru uz rizik slabije djelotvornosti.
You must not reduce your dose of INCIVO.
Ne smijete smanjivati dozu INCIVA koju uzimate.
Suppression by telaprevir and VRT-127394 of CYP enzymes regulated via CAR, PXR and Ah nuclear receptors was observed in vitro in human hepatocytes.
Zabilježena je supresija telaprevirom i VRT 127394 CYP enzima reguliranih putem CAR, PXR i Ah nuklearnih receptora in vitro, u humanih hepatocita.
Dosage adjustment of fentanyl or alfentanil may be necessary.
Može biti potrebna prilagodba doze fentanila ili alfentanila.
High density polyethylene (HDPE) bottle containing 42 film-coated tablets and fitted with polypropylene (PP) child resistant closure and induction seal liner.
Bočica od polietilena visoke gustoće (HDPE) koja sadrži 42 filmom obložene tablete i opremljena je polipropilenskim (PP) sigurnosnim zatvaračem za djecu i zaštitnom folijom.
A total of 215 of 1,169 patients treated with a T12/PR regimen in a Phase 3 clinical trial had on-treatment virologic failure (n = 125) or relapse (n = 90).
Ukupno je 215 od 1169 bolesnika liječenih režimom T12/PR u fazi III kliničkog ispitivanja imalo virološki neuspjeh tijekom liječenja (n = 125) ili relaps (n = 90).
Marked immunosuppressant dose reductions with or without prolongation of the dosing intervals will be required.
Biti će potrebno znatno sniziti dozu imunosupresiva s ili bez produljenja intervala doziranja.
- Anaemia (decrease in your red blood cells) Tell your doctor if you experience tiredness, weakness, shortness of breath, light-headedness, and/or the feeling of the heart racing.
- Anemija (smanjenje broja crvenih krvnih stanica) Obavijestite svog liječnika ako osjetite umor, slabost, nedostatak daha, ošamućenost i/ili osjećaj ubrzanog lupanja srca.
Refer to section 4.3 for HMG-CoA reductase inhibitors that are contraindicated with INCIVO.
Pogledati dio 4.3 za inhibitore HMG-CoA reduktaze koji su kontraindicirani s INCIVOM.
Female patients of childbearing potential and their male partners as well as male patients and their female partners must use 2 effective contraceptive methods during INCIVO treatment and afterwards as recommended in the Summary of Product Characteristics for ribavirin, and as described below.
Bolesnice reproduktivne dobi i njihovi muški partneri, kao i muški bolesnici i njihove partnerice, moraju koristiti 2 učinkovite kontracepcijske metode za vrijeme i nakon liječenja INCIVOM, kako je preporučeno u Sažetku opisa svojstava lijeka za ribavirin i opisano u daljnjem tekstu.
The exposure to telaprevir was increased by 20% when taken following a high-fat caloric meal (56 g fat, 928 kcal) compared to an intake following a standard normal caloric meal (21 g fat, 533 kcal).
Izloženost telapreviru bila je povećana za 20% kad se uzimao nakon kaloričnog obroka bogatog mastima (56 g masti, 928 kcal) u usporedbi s onom kad se uzimao nakon standardnog obroka normalne kalorijske vrijednosti (21 g masti, 533 kcal).
INCIVO has no or negligible influence on the ability to drive and use machines.
INCIVO ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
INCIVO is available in packs containing one bottle or 4 bottles per carton.
INCIVO je dostupan u pakiranjima s jednom ili 4 bočice po kutiji.
In vitro studies Activity of telaprevir against HCV
Djelovanje telaprevira protiv HCV-a
HCV variants associated with on-treatment virologic failure or relapse were evaluated by site-directed mutagenesis in the replicon assay.
Varijante HCV-a povezane s virološki neuspješnim liječenjem ili relapsom procijenile su se pomoću ciljane mutageneze (engl. site-directed mutagenesis) u replikonskom testu.
Concomitant administration of INCIVO and quetiapine is contraindicated as it may increase quetiapine-related toxicity.
Istodobna primjena lijekova INCIVO i kvetiapina je kontraindicirana jer može povisiti toksičnost povezanu s kvetiapinom.
These changes should be based on frequent monitoring of tacrolimus or cyclosporine A plasma concentrations during INCIVO treatment.
Ove promjene trebaju se temeljiti na čestom praćenju koncentracija takrolimusa ili ciklosporina A u plazmi za vrijeme liječenja INCIVOM.
Half the rashes started during the first 4 weeks, but rash can occur at any time during INCIVO combination treatment.
U pola slučajeva, osip je počeo u prva 4 tjedna liječenja, ali može se pojaviti u bilo koje vrijeme tijekom kombiniranog liječenja INCIVOM.
Detectable HCV RNA below the lower limit of assay quantification should not be used as a substitute for “undetectable” (target not detected), for making decisions on treatment duration, as this may lead to an insufficient duration of therapy and higher relapse rates.
Nalaz mjerljive HCV RNK, koja je ispod donje granice kvantifikacije testa, ne bi se smio uzeti kao „nemjerljiva” (cilj nije izmjeren) HCV RNK pri odlučivanju o trajanju liječenja, jer to može dovesti do nedovoljnog trajanja terapije i više stope relapsa.
When administered to lactating rats, levels of telaprevir and its major metabolite were higher in milk compared to those observed in plasma.
Kad se primjenjivao u štakora za vrijeme laktacije, koncentracije telaprevira i njegovog glavnog metabolita bile su više u mlijeku nego u plazmi.
Follow-up analysis of INCIVO-treated patients who did not achieve an SVR showed that the population of wild-type virus increased and the population of telaprevir-resistant variants became undetectable over time after the end of telaprevir treatment.
Analiza praćenih bolesnika liječenih INCIVOM koji nisu postigli SVR pokazala je da je populacija divljeg tipa virusa s vremenom rasla, a populacija varijanti rezistentnih na telaprevir postala nemjerljiva nakon završetka liječenja telaprevirom.
The direction of the arrow (↑ = increase, ↓ = decrease, ↔ = no change) for each pharmacokinetic parameter is based on the 90% confidence interval of the geometric mean ratio being within (↔), below (↓) or above (↑) the 80-125% range.
Smjer strjelice (↑ = povećanje, ↓ = smanjenje, ↔ = bez promjene) za svaki farmakokinetički parametar temelji se na intervalu pouzdanosti od 90% geometrijske sredine omjera koji je unutar (↔), ispod (↓) ili iznad (↑) raspona od 80% do 125%.
Caution is warranted and clinical monitoring is recommended when intravenous lidocaine is administered for the treatment of acute ventricular arrhythmia.
Nalaže se oprez i preporučuje klinički nadzor kad se intravenski lidokain primjenjuje za liječenje akutne ventrikularne aritmije.
To prevent treatment failure, the dose of INCIVO must not be reduced or interrupted.
Kako bi se spriječio neuspjeh liječenja, ne smije se smanjiti doza niti prekinuti primjena INCIVA.
For additional information on mild to moderate rash, see section 4.8.
Za dodatne informacije o blagom do umjerenom osipu, vidjeti dio 4.8.
HCV RNA levels should be monitored at weeks 4 and 12 and as clinically indicated (see also guidelines for discontinuation of INCIVO, section 4.2).
Vrijednosti HCV RNK treba pratiti u 4. i 12. tjednu te kad je to klinički indicirano (vidjeti također smjernice za prestanak primjene INCIVA, dio 4.2).
IL28B genotype CC
IL28B genotip
If you are breast-feeding, you must stop breast-feeding before starting to take INCIVO.
Ako dojite, morate prestati dojiti prije početka uzimanja INCIVA.
Note that the virologic stopping rules taken into account in this treatment outcome analysis are actual stopping rules, i.e., those derived from disposition and exposure data, as opposed to mathematical stopping rules, i.e., derived from the
Napomena, virološka pravila za prekid uzeta u obzir u ovoj analizi ishoda liječenja, su stvarna pravila za prekid, tj. ona izvedena iz podataka dispozicije i izloženosti, što je suprotno od matematičkih pravila za prekid, npr. izvedenih iz HCV RNK podataka.
Efficacy in adults with HCV/HIV-1 co-infection
Djelotvornost u odraslih s istodobnom HCV/HIV-1 infekcijom
Yellow caplet-shaped tablets of approximately 20 mm in length, marked with ‘T375' on one side.
Žute tablete ovalnog oblika duljine oko 20 mm, s oznakom “T375” na jednoj strani.
Contact your doctor immediately also if you develop any of the following symptoms: - tiredness, weakness, shortness of breath, light-headedness, and/or feeling of heart racing.
Odmah se javite liječniku i ako se razvije neki od sljedećih simptoma: - umor, slabost, nedostatak daha, ošamućenost i/ili osjećate ubrzan rad srca.
Median (range) CD4 cell count at baseline was 651 (277 to 1,551 cells/mm
Medijan (raspon) broja CD4 stanica na početku bio je 651 (277 do 1551 stanica/mm
- if you have a wide-spread rash with peeling skin which may be accompanied by fever, flu-like symptoms, painful skin blisters, and blisters in the mouth, eyes, and/or genitals.
- ako imate prošireni osip s ljuštenjem kože koji može biti praćen vrućicom, simptomima sličnima gripi, bolnim mjehurićima na koži i mjehurićima u ustima, na očima i/ili spolnim
Concomitant administration with Class Ia or III antiarrhythmics, except for intravenous lidocaine (see section 4.5).
Istodobna primjena s antiaritmicima skupine Ia ili III, osim intravenskog lidokaina (vidjeti dio 4.5).
Refer to sections 4.4 and 4.6.
Vidjeti dijelove 4.4 i 4.6.
If ribavirin is permanently discontinued for the management of anaemia, INCIVO must also be permanently discontinued.
Ako se primjena ribavirina trajno prekine radi zbrinjavanja anemije, mora se trajno prekinuti i primjena INCIVA.
Carbamazepine, phenytoin and phenobarbital
Karbamazepin, fenitoin i fenobarbital
Use of INCIVO should be avoided in patients with congenital QT prolongation, or a family history of congenital QT prolongation or sudden death.
Primjenu INCIVA treba izbjegavati u bolesnika s kongenitalnim produljenjem QT intervala ili s kongenitalnim produljenjem QT intervala ili iznenadnom smrću u obiteljskoj anamnezi.
Tablet film-coat polyvinyl alcohol macrogol talc titanium dioxide (E171) iron oxide yellow (E172)
Film ovojnica tablete polivinilni alkohol, makrogol, talk, titanijev dioksid (E171), željezov oksid, žuti (E172)
Prescribers should ensure that patients are fully informed about the risk of severe rashes, and to consult with their prescriber immediately if they develop a new rash or worsening of an existing rash.
Liječnici koji propisuju lijek trebaju bolesnike u potpunosti upoznati s rizikom pojave teških osipa te ih upozoriti da se odmah moraju javiti liječniku ako se pojavi novi ili pogorša postojeći osip.
Please consult sections 4.4 and 5.1 regarding the selection of peginterferon alfa-2a or -2b.
Molimo vidjeti dijelove 4.4 i 5.1 vezano uz odabir peginterferona alfa-2a ili -2b.
After oral administration, the typical apparent volume of distribution (Vd) was estimated to be 252 l, with an inter-individual variability of 72.2%.
Nakon peroralne primjene, tipični prividni volumen raspodjele (Vd) približno je bio 252 l, uz varijacije između osoba od 72,2%.